GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascentage Pharma Group International (HKSE:06855) » Definitions » EPS without NRI

Ascentage Pharma Group International (HKSE:06855) EPS without NRI : HK$-1.45 (TTM As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Ascentage Pharma Group International EPS without NRI?

Ascentage Pharma Group International's earnings per share without non-recurring items for the six months ended in Dec. 2024 was HK$-2.04. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-1.45.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 29.00% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 27.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Ascentage Pharma Group International's EPS without NRI or its related term are showing as below:

HKSE:06855' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -176.5   Med: -11.95   Max: 35.1
Current: 29

During the past 9 years, Ascentage Pharma Group International's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 35.10% per year. The lowest was -176.50% per year. And the median was -11.95% per year.

HKSE:06855's 3-Year EPS without NRI Growth Rate is ranked better than
71.85% of 1229 companies
in the Biotechnology industry
Industry Median: 10.3 vs HKSE:06855: 29.00

Ascentage Pharma Group International's EPS (Diluted) for the six months ended in Dec. 2024 was HK$-2.03. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-1.44.

Ascentage Pharma Group International's EPS (Basic) for the six months ended in Dec. 2024 was HK$-2.03. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-1.43.


Ascentage Pharma Group International EPS without NRI Historical Data

The historical data trend for Ascentage Pharma Group International's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascentage Pharma Group International EPS without NRI Chart

Ascentage Pharma Group International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EPS without NRI
Get a 7-Day Free Trial Premium Member Only -3.71 -4.03 -3.78 -3.60 -1.45

Ascentage Pharma Group International Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.98 -1.62 -1.98 0.59 -2.04

Competitive Comparison of Ascentage Pharma Group International's EPS without NRI

For the Biotechnology subindustry, Ascentage Pharma Group International's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascentage Pharma Group International's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascentage Pharma Group International's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Ascentage Pharma Group International's PE Ratio without NRI falls into.


;
;

Ascentage Pharma Group International EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-1.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ascentage Pharma Group International  (HKSE:06855) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Ascentage Pharma Group International EPS without NRI Related Terms

Thank you for viewing the detailed overview of Ascentage Pharma Group International's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascentage Pharma Group International Business Description

Traded in Other Exchanges
Address
68 Xinqing Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215000
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.
Executives
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Takeda Pharmaceuticals International Ag 2101 Beneficial owner
Takeda Pharmaceuticals Company Limited 2201 Interest of corporation controlled by you
Gao Sharon Xia
Zhai Yifan
Yang Dajun
Wang Shaomeng
Li Ju-yun
Healthquest Pharma Limited
Guo Edward Ming
Ascentage Limited
South Dakota Trust Company Llc 2301 Trustee
Tian Yuan 2201 Interest of corporation controlled by you
Zhao Li 2202 Interest of your spouse
Xian Jin Zhi Zao Chan Ye Tou Zi Ji Jin You Xian He Huo 2201 Interest of corporation controlled by you

Ascentage Pharma Group International Headlines

No Headlines